Osimertinib, also known as Tagrisso, is a targeted therapy. It is used for treating NSCLC (NSCLC).In this context, HSE refers to health provisions and care. These are provided for individuals receiving osimertinib therapy.The aim of this article is to provide a comprehensive overview of osimertinib healthcare support. It highlights its significance, problems, and possible solutions.osimertinib healthcare support includes a wide variety of health provisions. These are patient information, drug administration, careive care, and psychosocial care.For individuals to ensure the effectiveness and standard of their therapy, it is crucial that they…
